Samantha C Sodergren1, Sally J Wheelwright1, Deborah Fitzsimmons2, Fabio Efficace3, Mirjam Sprangers4, Peter Fayers5, Amelie Harle6, Heike Schmidt7, Andrew Bottomley8, Anne-Sophie Darlington1, Charlotte Benson9, Anne Bredart10, Leopold Hentschel11, Juan Ignacio Arraras12, Georgios Ioannidis13, Michael Leahy14, Iwona Lugowska15, Ourania Nicolatou-Galitis16, Duska Petranovic17, Gudrun E Rohde18,19, Vasilis Vassiliou20, Colin D Johnson21. 1. School of Health Sciences, University of Southampton, Southampton, UK. 2. Public Health, Policy and Social Sciences, University of Swansea, Swansea, UK. 3. Italian Group for Adult Hematologic Disease (GIMEMA), Rome, Italy. 4. Department of Medical Psychology, Amsterdam University Medical Center, Amsterdam, The Netherlands. 5. Medical Science and Nutrition, Aberdeen University School of Medicine, Aberdeen, UK. 6. Poole Hospital NHS Foundation Trust, Poole, UK. 7. Martin Luther University Halle-Wittenberg, Halle, Germany. 8. EORTC Quality of Life Department, Brussels, Belgium. 9. The Royal Marsden NHS Foundation Trust, Sutton, UK. 10. Institut Curie, Paris, France. 11. University Hospital Carl Gustav Carus, Dresden, Germany. 12. Complejo Hospitalario de Navarra, Navarra, Spain. 13. Nicosia General Hospital, Nicosia, Cyprus. 14. The Christie NHS Foundation Trust, Manchester, UK. 15. Maria Sklodowska-Curie Memorial Cancer Centre-Institute of Oncology, Warsaw, Poland. 16. National & Kapodistrian University of Athens, Athens, Greece. 17. University Clinical Hospital Center Rijeka, Rijeka, Croatia. 18. Faculty of Health and Sport Sciences, University of Adger, Agder, Norway. 19. Sørlandet Hospital, Kristiansand, Norway. 20. Bank of Cyprus Oncology Centre, Nicosia, Cyprus. 21. Cancer Sciences, University of Southampton, Southampton, UK. c.d.johnson@soton.ac.uk.
Abstract
BACKGROUND: Targeted therapies (TTs) have revolutionised cancer treatment with their enhanced specificity of action. Compared with conventional therapies, TTs are delivered over a longer period and often have unusual symptom profiles. Patient-reported outcome measures such as symptom side-effect lists need to be developed in a time-efficient manner to enable a rapid and full evaluation of new treatments and effective clinical management OBJECTIVE: The aim of this study was to develop a set of TT-related symptoms and identify the optimal method for developing symptom lists. PATIENTS AND METHODS: Symptoms from TT treatment in the context of Chronic Myeloid Leukaemia (CML), HER2-positive breast cancer, or Gastrointestinal Stromal Tumours (GIST) were identified through literature reviews, interviews with healthcare professionals (HCPs) and patients, and patient focus groups. The symptom set was then pilot tested in patients across the three cancer diagnoses: The number of items derived from each source (literature, patients, or HCPs) were compared. RESULTS: A total of 316 patients and 86 HCPs from 16 countries participated. An initial set of 209 symptoms was reduced to 61 covering 12 symptom categories. Patient interviews made the greatest contribution to the item set. CONCLUSIONS: Symptom lists should be created based on input from patients. The item set described will be applicable to the assessment of new TTs, and in monitoring treatment.
BACKGROUND: Targeted therapies (TTs) have revolutionised cancer treatment with their enhanced specificity of action. Compared with conventional therapies, TTs are delivered over a longer period and often have unusual symptom profiles. Patient-reported outcome measures such as symptom side-effect lists need to be developed in a time-efficient manner to enable a rapid and full evaluation of new treatments and effective clinical management OBJECTIVE: The aim of this study was to develop a set of TT-related symptoms and identify the optimal method for developing symptom lists. PATIENTS AND METHODS: Symptoms from TT treatment in the context of Chronic Myeloid Leukaemia (CML), HER2-positive breast cancer, or Gastrointestinal Stromal Tumours (GIST) were identified through literature reviews, interviews with healthcare professionals (HCPs) and patients, and patient focus groups. The symptom set was then pilot tested in patients across the three cancer diagnoses: The number of items derived from each source (literature, patients, or HCPs) were compared. RESULTS: A total of 316 patients and 86 HCPs from 16 countries participated. An initial set of 209 symptoms was reduced to 61 covering 12 symptom categories. Patient interviews made the greatest contribution to the item set. CONCLUSIONS: Symptom lists should be created based on input from patients. The item set described will be applicable to the assessment of new TTs, and in monitoring treatment.
Authors: Deborah van de Wal; Mai Elie; Axel Le Cesne; Elena Fumagalli; Dide den Hollander; Robin L Jones; Gloria Marquina; Neeltje Steeghs; Winette T A van der Graaf; Olga Husson Journal: Cancers (Basel) Date: 2022-04-05 Impact factor: 6.639
Authors: Dide den Hollander; Anne R Dirkson; Suzan Verberne; Wessel Kraaij; Gerard van Oortmerssen; Hans Gelderblom; Astrid Oosten; Anna K L Reyners; Neeltje Steeghs; Winette T A van der Graaf; Ingrid M E Desar; Olga Husson Journal: Support Care Cancer Date: 2022-03-02 Impact factor: 3.359